These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19531900)

  • 1. Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients.
    Abe M; Kimura T; Morimoto T; Furukawa Y; Kita T
    Circ J; 2009 Aug; 73(8):1518-22. PubMed ID: 19531900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic hemodialysis does not prevent contrast-induced nephropathy after cardiac catheterization in patients with chronic renal insufficiency.
    Kawashima S; Takano H; Iino Y; Takayama M; Takano T
    Circ J; 2006 May; 70(5):553-8. PubMed ID: 16636489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of contrast-induced nephropathy by the serum creatinine level on the day following cardiac catheterization.
    Watanabe M; Saito Y; Aonuma K; Hirayama A; Tamaki N; Tsutsui H; Murohara T; Ogawa H; Akasaka T; Yoshimura M; Sato A; Takayama T; Sakakibara M; Suzuki S; Ishigami K; Onoue K;
    J Cardiol; 2016 Nov; 68(5):412-418. PubMed ID: 26708123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization: From the CINC-J study.
    Sato A; Aonuma K; Watanabe M; Hirayama A; Tamaki N; Tsutsui H; Toyoaki M; Ogawa H; Akasaka T; Yoshimura M; Takayama T; Sakakibara M; Suzuki S; Ishigami K; Onoue K; Saito Y;
    Int J Cardiol; 2017 Jan; 227():424-429. PubMed ID: 27838134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome.
    Senoo T; Motohiro M; Kamihata H; Yamamoto S; Isono T; Manabe K; Sakuma T; Yoshida S; Sutani Y; Iwasaka T
    Am J Cardiol; 2010 Mar; 105(5):624-8. PubMed ID: 20185007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients.
    Sany D; Refaat H; Elshahawy Y; Mohab A; Ezzat H
    Ren Fail; 2014 Mar; 36(2):191-7. PubMed ID: 24138570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-Induced Nephropathy After Cardiac Catheterization: Culprits, Consequences and Predictors.
    Sedhai YR; Golamari R; Timalsina S; Basnyat S; Koirala A; Asija A; Choksi T; Kushwah A; Geovorgyan D; Dar T; Borikar M; Ahangar W; Alukal J; Zia S; Missri J
    Am J Med Sci; 2017 Nov; 354(5):462-466. PubMed ID: 29173356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis.
    Ye Z; Lu H; Su Q; Guo W; Dai W; Li H; Yang H; Li L
    Medicine (Baltimore); 2017 Mar; 96(9):e6059. PubMed ID: 28248861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sex on the risk to develop contrast-induced nephropathy after transcatheter aortic valve implantation.
    Madershahian N; Scherner M; Rudolph T; Slottosch I; Grundmann F; Kuhn E; Michels G; Wahlers T
    Innovations (Phila); 2014; 9(2):87-92; discussion 92. PubMed ID: 24758950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.
    Chen F; Liu F; Lu J; Yang X; Xiao B; Jin Y; Zhang J
    Eur J Med Res; 2018 May; 23(1):23. PubMed ID: 29776437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-Induced Nephropathy in STEMI Patients With and Without Chronic Kidney Disease.
    Jain T; Shah S; Shah J; Jacobsen G; Khandelwal A
    Crit Pathw Cardiol; 2018 Mar; 17(1):25-31. PubMed ID: 29432373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contrast-induced nephropathy after cardiac catheterization: a prospective study of 180 patients].
    Mghaieth F; Ayari J; Ben Rejeb R; Mbarki S; Farhati A; Larbi N; Boussaada R; Mourali MS; Mechmeche R
    Tunis Med; 2012 Apr; 90(4):320-7. PubMed ID: 22535348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-induced nephropathy after percutaneous coronary intervention in simple lesions: risk factors and incidence are affected by the definition utilized.
    Caruso M; Balasus F; Incalcaterra E; Ruggieri A; Evola S; Fattouch K; Bracale UM; Amodio E; Novo G; Andolina G; Novo S
    Intern Med; 2011; 50(9):983-9. PubMed ID: 21532220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.